Prognostic Value of Stem Cell Related Markers CD24, CD44, CD326 and EPCR, for Predicting Breast Cancer Recurrence in Tumor Stages 0-II
N/A
18 Years
N/A
18 Years
N/A
Not Enrolling
Female
Breast Cancer
Female
Breast Cancer
Trial Information
Prognostic Value of Stem Cell Related Markers CD24, CD44, CD326 and EPCR, for Predicting Breast Cancer Recurrence in Tumor Stages 0-II
Inclusion Criteria:
- Ductal Carcinoma in Situ
- DCIS + Microinvasion stages 1 or 11 without positive lymph nodes
Exclusion Criteria:
- tumor specimen with higher than grade II
- BRACA 1 or BRACA 2 mutation
- Neoadjuvant chemotherapy
Type of Study:
Observational
Study Design:
Observational Model: Case-Only
Authority:
Israel: Ministry of Health
Study ID:
10.CTIL
NCT ID:
NCT01265225
Start Date:
February 2011
Completion Date:
April 2013
Related Keywords:
- Breast Cancer
- breast cancer stages 0-II
- Breast Neoplasms
Name | Location |
|---|
